Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Muscle Damage Due to Fusidic AcidStatin Interaction

Review of 75 Cases From the French Pharmacovigilance Database and Literature Reports

Bataillard, Maxime1,*; Beyens, Marie-Noëlle MD2; Mounier, Geneviève PharmD2; Vergnon-Miszczycha, Delphine MD1; Bagheri, Haleh PharmD3; Cathebras, Pascal MD1

American Journal of Therapeutics: May/June 2019 - Volume 26 - Issue 3 - p e375–e379
doi: 10.1097/MJT.0000000000000679
Systematic Reviews
Buy

Background/Area of Uncertainty: Statins, which reduce cardiovascular risk in both primary and secondary prevention, are one of the most widely prescribed therapeutic classes in the world. Usually well-tolerated, statin-associated muscle symptoms are a well-known adverse effect. Fusidic acid (FA) is a bacteriostatic antibiotic of interest in the treatment of methicillin-resistant Staphylococcus aureus infections. Cases of rhabdomyolysis, sometimes fatal, have been reported after coprescription of FA and a statin.

Data Sources/Area of Uncertainty: We studied 75 cases of muscle damage related to interaction between FA and a statin reported in the French national pharmacovigilance database (43 cases) and from a literature review (32 cases).

Results: Cases were mostly men (72.5%), often overweight (mean body mass index: 29.4). The most commonly reported statins were atorvastatin (60%), simvastatin (22.7%), and rosuvastatin (8.0%). Muscle disorders appeared on average 30 days after initiation of FA. Symptoms were muscle weakness (82%), dark urine (71%), and myalgia (61%). Mean creatine kinase level at diagnosis was 43,890 UI/mL, and acute renal injury occurred more than half of the cases. Outcome was fatal in 22% of cases and 28% kept sequelae at the end of the follow-up (54 days).

Conclusions: Muscle damage induced by interaction between FA and statin is a potentially life-threatening complication, leading to contraindication of this association in France. This is to be reminded especially because FA is about to get FDA approval and should soon be available in the United States.

1Internal Medicine Department, University Hospital of Saint-Etienne, Saint-Etienne, France;

2Department of Pharmacovigilance, University Hospital of Saint-Etienne, Saint-Etienne, France; and

3Department of Pharmacovigilance, University Hospital of Toulouse, Toulouse, France.

Address for correspondence: Internal Medicine Department, University Hospital of Saint-Etienne, 42055 Saint-Etienne cedex 2, France. E-mail: maxime.bataillard@gmail.com

The authors have no conflicts of interest to declare.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.